The most recent trading session ended with Johnson & Johnson (JNJ) standing at $150.47, reflecting a -1.24% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the day. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.31%.The the stock of world's biggest maker of health care products has fallen by 3.78% in the past month, lagging the Medical sector's loss of 1.45% and the S&P 500's gain of 5.79%.Investors will be eagerly watching for the perform ...

Johnson & Johnson (JNJ) announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.While one sBLA seeks approval of Tremfya for treating children 6 years and older with moderate-to-severe plaque psoriasis (PsO), the other one is for children 5 years of age and older with active juvenile psoriatic arthritis (jPsA).Tremfya, an IL-23 inhibitor, is already approved to treat certain adult patients with plaque psoriasis and act ...

Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis  SPRING HOUSE, Pa., Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older wi ...

BRIDGEWATER, N.J. and BENGALURU, India, Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce), a biosimilar to the reference product, Stelara® (Ustekinumab). YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic a ...

Allocating the largest proportion of your dividend portfolio to Johnson & Johnson (NYSE: JNJ ) (NEOE: JNJ:CA ) can help you to effectively reduce the volatility of your investment portfolio, serving as a strategic defensive move toI specialize in constructing investment portfolios aimed at generating additional income through dividends. My focus lies on identifying companies with significant competitive advantages and strong financials that can provide you with an attractive Dividend Yield and Dividend Grow ...

Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.That won't be a problem with Johnson & Johnson (JNJ 0.39%) and Medtronic (MDT -0.53%). They're healthy companies that should continue to pay durable dividends in the decades ahead, making them great income investments. As healthy as it getsJohnson & Johnson is among the world's healthiest companies. The healthcare gia ...

Johnson & Johnson (JNJ) announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine Tremfya (guselkumab) in ulcerative colitis (UC) indication. The FDA recently approved Tremfya to treat adults with moderately to severely active UC as both an induction and maintenance therapy. However, the induction dose of the drug can only be administered as an intravenous (IV) therapy. The maintenance dose of ...

Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.Dividends can be a great way to increase your returns with time while giving you extra capital to reinvest or keep in your portfolio. These kinds of stocks can be found across many different sectors and industries.If you're looking for two top dividend stocks to consider for your portfolio and have $500 available ...

Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.When it comes to Dividend Elite’s, at the top of the hierarchy are Dividend Kings. Dividend Kings are defined as companies that have increased their dividend for 50+ consecutive years.Brad, along with HOYA Capital, lead the investing group iREIT®+HOYA Cap ...

POLAND - 2024/11/17: In this photo illustration, the AbbVie company logo is seen displayed on a ... [+] smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings. However, we think that the new drugs that are gaining market ...